# Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Study · id `cardio:ct-nct06767774` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06767774](<https://clinicaltrials.gov/study/NCT06767774>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06767774

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT06767774. Randomized; no masking; primary purpose prevention. Start 2025-04-25 (actual); primary completion 2029-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT06767774, source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)
- Started: 2025-04-25 (actual) (ClinicalTrials.gov record NCT06767774, source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)
- Primary completion: 2029-08-31 (anticipated) (ClinicalTrials.gov record NCT06767774, source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)
- Completion: 2030-01-31 (anticipated) (ClinicalTrials.gov record NCT06767774, source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06767774, source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06767774-2025-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
- Condition: ASCVD
- Condition: Diabetes
- Condition: Statin
- Intervention (Drug): Combination therapy
- Intervention (Drug): High intensity statin monotherapy
- Lead sponsor: Korea University Anam Hospital
- Lead sponsor class: OTHER
- Collaborator: Daewon Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY
- Collaborator: Samjin Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)
- Registry lists this organization as a collaborator: Daewon Pharmaceutical Co., Ltd. (`cardio:org-daewon-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Samjin Pharmaceutical Co., Ltd. (`cardio:org-samjin-pharmaceutical-co-ltd`)

## Provenance

Content hash: d20e1a7a3d5a80981ea7c28520d971a26964ef88b1be31bddd9c57c3592e766c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
